HUTCHMED Announces NDA Acceptance In China For Savolitinib In MET-Amplified Gastric Cancer

HUTCHMED announced China's NMPA has accepted its NDA for savolitinib (ORPATHYS) for MET‑amplified locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma after ≥2 prior systemic therapies and granted priority review; the submission is supported by a Phase II registration study that met its primary ORR endpoint and the drug already holds Breakthrough Therapy designation. Savolitinib, jointly developed with AstraZeneca and already approved in China for METex14 NSCLC and listed on the National Reimbursement Drug List, could become the first selective MET inhibitor for this gastric cancer subgroup (~18,000 annual cases in China), addressing a clear unmet need. ORPATHYS sales were $9.0M in H1 2025 versus $13.1M year‑ago; HUTCHMED shares traded between $11.51–$19.50 in the past year and closed at $13.40 (-2.62%).

Analysis

Market structure: Approval of savolitinib for MET‑amplified gastric cancer primarily benefits HCM (direct revenue), AZN (co‑developer upside) and diagnostic labs that will bill for MET testing; losers are non‑targeted chemo vendors and any late‑entrants without selective MET assets. Addressable China incidence ~18,000/year (4–6%); capturing 20–30% share implies 3.6k–5.4k patients — enough for a mid‑teens to low‑hundreds of millions RMB peak annual sales if pricing is premium and reimbursement follows.

Risk assessment: Near‑term risk is regulatory reversal or conditional approval tied to limited ORR data (no mature OS), with a meaningful downside if NMPA imposes restrictive label or price controls. Timeframes: immediate (days) — IV/vol move and sentiment; short (1–6 months) — pricing/reimbursement talks and guideline inclusion; long (1–3 years) — penetration contingent on MET testing rollout, combos and real‑world safety. Hidden dependency: diagnostic capacity — revenue growth stalls if MET testing <50% of eligible patients within 12 months.

Trade implications: Direct tactical long bias in HCM with defined risk sizing; AZN gets small option-like exposure to upside of global combo programs. Use options to buy convexity ahead of the NMPA decision (9–12 month call spreads) rather than naked equity to limit tail loss; hedge biotech beta by shorting a broad biotech ETF (XBI) or using puts. Monitor thresholds: approval within 6 months and payer pricing that allows per‑patient reimbursement >$X (company to disclose) as go/no‑go signals.

Contrarian angles: Consensus overweights headline approval probability and underestimates bottlenecks — if MET testing adoption remains <40–50% the market will materially underdeliver vs expectations. Conversely, market may underprice AZN’s optionality if savolitinib combos show synergy globally. Unintended consequence: fast approval could trigger rapid price negotiations or compulsory reimbursement caps, compressing longer‑term margins.

Key Decisions for Investors

• Establish a 2–3% long position in HCM (ticker HCM) within 1–4 weeks while IV is elevated; set tactical take‑profit at +40–80% on approval news (expected within ~3–6 months under priority review) and a hard stop at −30% to limit downside if regulatory outcome turns negative.
• Buy a 9–12 month HCM call spread (long Jan 2026 15 strike calls / short Jan 2026 25 strike calls, size equivalent to 1–2% notional) to capture approval upside with capped cost and defined P/L; reprice or unwind if MET testing penetration >50% in China within 9–12 months.
• Allocate 0.5–1.0% long to AZN (ticker AZN) to capture downstream combo/global upside — treat as optionality and trim if savolitinib shows no incremental clinical signals in 2–4 quarters; pair with a 0.5–1% short position in XBI (SPDR S&P Biotech ETF) to hedge sector idiosyncratic risk.
• Reduce exposure to Chinese small‑cap oncology names by 2–4% and reallocate to diagnostic playmakers (labs/PDx) if MET testing rollout accelerates; require MET testing adoption >50% of eligible gastric patients within 12 months as a condition to increase HCM exposure above 3%.